Please ensure Javascript is enabled for purposes of website accessibility

Different standards for name-brand, generic drugs (access required)

WASHINGTON — The Supreme Court decision late last month that state-law failure-to-warn claims against generic drug makers are preempted by federal law — handed down just two years after the Court held that brand-name drug makers could face such suits — creates a legal discrepancy that leaves the majority of patients without recourse, some advocates ...